HER2-Positive Gastric Adenocarcinoma — Trials

HER2-Positive Gastric Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 6
Ph III recruiting: 2
Growth YoY: —
Industry share: 40%
Top sponsor: Qilu Hospital of Shandong University
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (7)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06253650	Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY)	recruiting	Phase 2	46	Gruppo Oncologico del Nord-OvestOTHER	1	Sep 23, 2026	clinicaltrials
NCT06730373	First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)	recruiting	Phase 2	110	Qilu Hospital of Shandong UniversityOTHER	1	Sep 15, 2026